These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 535134)

  • 1. Human pharmacokinetics of the daunorubicin-DNA complex. An alternative view of the lysosomotropic theory.
    Hulhoven R; Sokal G; Harvengt C
    Cancer Chemother Pharmacol; 1979; 3(4):243-7. PubMed ID: 535134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution of daunorubicin intravenously injected or intravenously infused as free drug and as a complex with DNA in rabbits.
    Hulhoven R; Harvengt C
    Pharmacology; 1982; 24(4):253-60. PubMed ID: 7089047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of daunorubicinol in the rabbit: comparison with daunorubicin.
    Maniez-Devos DM; Baurain R; Trouet A; Lesne M
    J Pharmacol; 1986; 17(1):14-20. PubMed ID: 3713197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex.
    Andersson B; Beran M
    Cancer Chemother Pharmacol; 1980; 4(3):205-7. PubMed ID: 7397945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daunorubicin, daunorubicinol and DNA plasma kinetics after I.V. administration of daunorubicin-DNA complex in the rabbit. II. -- Effects of R. E. S.-blockade.
    Hulhoven R; Haravengt C
    Biomedicine; 1980 Apr; 33(2):44-7. PubMed ID: 7407324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of daunorubicin and doxorubicin, free and associated with DNA, on hemopoietic stem cells.
    Huybrechts M; Symann M; Trouet A
    Cancer Res; 1979 Sep; 39(9):3738-43. PubMed ID: 476697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia.
    Pea F; Russo D; Michieli M; Baraldo M; Ermacora A; Damiani D; Baccarani M; Furlanut M
    Cancer Chemother Pharmacol; 2000; 46(4):279-86. PubMed ID: 11052625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daunorubicin, daunorubicinol and DNA plasma kinetics after I.V. administration of daunorubican-DNA complex in the rabbit.
    Hulhoven R
    Biomedicine; 1978 Jul; 29(5):164-7. PubMed ID: 719130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics and sensitivity of daunorubicin in patients with acute leukemia.
    DeGregorio MW; Holleran WM; Macher BA; Linker CA; Wilbur JR
    Cancer Chemother Pharmacol; 1984; 13(3):230-4. PubMed ID: 6488444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.
    Berman E; McBride M; Lin S; Menedez-Botet C; Tong W
    Leukemia; 1995 Oct; 9(10):1631-7. PubMed ID: 7564501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPLC determination of daunorubicin and daunorubicinol in human plasma.
    Hulhoven R; Desager JP
    Biomedicine; 1977 Apr; 27(3):102-4. PubMed ID: 890014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of daunorubicin and its main metabolites in plasma, urine and leukaemic cells in patients with acute myeloblastic leukaemia.
    Paul C; Baurain R; Gahrton G; Peterson C
    Cancer Lett; 1980 Jun; 9(4):263-9. PubMed ID: 6930988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake and metabolism of daunorubicin by human leukemia cells.
    DeGregorio MW; Carrera CJ; Klock JC; Wilbur JR
    Cancer Chemother Pharmacol; 1982 Dec; 10(1):29-32. PubMed ID: 6961971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients.
    Nilsson SO; Andersson B; Eksborg S; Beran M; Ehrsson H
    Cancer Chemother Pharmacol; 1981; 5(4):261-6. PubMed ID: 7261253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia.
    Kokenberg E; Sonneveld P; Sizoo W; Hagenbeek A; Löwenberg B
    J Clin Oncol; 1988 May; 6(5):802-12. PubMed ID: 3163363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.
    Trouet A; Masquelier M; Baurain R; Deprez-De Campeneere D
    Proc Natl Acad Sci U S A; 1982 Jan; 79(2):626-9. PubMed ID: 6952214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion.
    Masquelier M; Baurain R; Trouet A
    J Med Chem; 1980 Nov; 23(11):1166-70. PubMed ID: 7452665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia.
    Galettis P; Boutagy J; Ma DD
    Br J Cancer; 1994 Aug; 70(2):324-9. PubMed ID: 7914424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.
    Tidefelt U; Liliemark J; Gruber A; Liliemark E; Sundman-Engberg B; Juliusson G; Stenke L; Elmhorn-Rosenborg A; Möllgård L; Lehman S; Xu D; Covelli A; Gustavsson B; Paul C
    J Clin Oncol; 2000 May; 18(9):1837-44. PubMed ID: 10784624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia.
    Bogason A; Quartino AL; Lafolie P; Masquelier M; Karlsson MO; Paul C; Gruber A; Vitols S
    Br J Clin Pharmacol; 2011 Apr; 71(4):514-21. PubMed ID: 21204910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.